The goal of this study was to address whether antiislet autoantibodies appear sequentially or simultaneously before the onset of type I diabetes.
We 
Results
Autoantibody conversion events were defined as the confirmed appearance (negative sample followed by 22 sequential positive samples) of IAA, GAA, or ICA512AA. From the total 26 conversion events observed, 6 patterns of conversion were detected (O-+1 antibody (Ab); O-+1-+2 Ab; O-+2 Ab; 1-2 Ab, l-2-+3 Ab, and 2-+3 Ab). Figure 1 provides quantitative data for single individuals illustrating each of the 6 patterns. The data are presented as a SD score [(sample antibody index -control mean index) / control SD] to aid comparison between different autoantibodies. The y-axis of each of the panels is on a log scale and illustrates the magnitude of the response. As illustrated, many relatives who were initially autoantibody negative (with SD score <3) developed high levels of autoantibodies, often exceeding 30-100 SD above normal.
The sibling and offspring cohort of DAISY was evaluated for all 3 autoantibodies from the time of first testing. Of 155 of these relatives, 150 have remained negative (Table 1) for all autoantibodies on sequential evaluations (O+O Ab). Five converters were observed among the 155 DAISY relatives with 2 individuals acquiring their first autoantibody, 2 converting from 1 to 2, and 1 converting from 1 to 3 autoantibodies. For none of the DAISY converters did more than 1 autoantibody appear simultaneously. Twenty-one conversion events were observed in separate groups of relatives from family studies at the Joslin Diabetes Center and the Barbara Davis Center.
Of the total of 26 conversion events, in only 3 instances did more than 1 autoantibody appear simultaneously (Table 1 ). For the 3 converters acquiring 2 autoantibodies "simultaneously," the intervals from the last negative determination to the positive follow-up serum sample were 0.25, 1.8, and 6 yr.
Among the group who subsequently expressed 2 or more autoantibodies, 8 individuals expressed GAA as their first autoantibody, 4 individuals expressed IAA as their first autoantibody, and none was found to express ICA512AA first (although 8 of 26 converters eventually expressed ICA512AA).
Two children of the DAISY cohort were found to develop their first autoantibody under the age of 1 yr ( Table 2) . One of these children developed a second autoantibody after 6 months and another sequentially developed all three autoantibodies within 2 yr (neither of these children is currently diabetic). Among adults, three did not show detectable autoantibodies until late in life (30-50 yr of age). One of these adults developed 2 autoantibodies simultaneously at the age of 41 yr, and another developed a first autoantibody (GAA) after the age of 50 yr and a second autoantibody (IAA) after age 60 yr.
The interval between sequential development of multiple autoantibodies (0+1-+2+3 Ab) was widely variable. Some individuals maintained single autoantibody positivity for 10 yr before a second autoantibody appeared, whereas some individuals remained single autoantibody positive only for several months and sequentially developed all three autoantibodies within 2 yr. Life table analysis was performed comparing the intervals between acquisition of an additional autoantibody and HLA-DR3 / DR4 status. No significant difference (P = 0.09 by the log rank test and P = 0.26, by the Wilcoxon test) was found between the DR3/4 and non-DR3/4 groups.
Of the group of 26 converters, 7 to date have progressed to overt diabetes. All of these individuals expressed multiple autoantibodies before disease onset ( Table 2) . Six of 7 progressed to overt diabetes in less than 2.5 yr from the final ascertained autoantibody conversion. One child, who was initially double autoantibody positive (GAA and IAA) at 7 yr of age, acquired ICA512AA at age 9 yr and then expressed 3 autoantibodies for over 8 yr before progressing to overt diabetes.
Discussion
One hypothesis for the etiology of type I diabetes postulates acute environmentally induced P-cell destruction, which activates widespread antiislet autoimmunity. In the current study using three autoantibody radioassays (GAA, IAA, and ICA512AA), sequential appearance of autoantibodies was generally found (23 of 26 individuals). When more than a single autoantibody showed positivity for the first time in the same serum sample, the intervals from the YU, REWERS, GIANANI, ET AL. Islet autoantibodies can develop both very early (8) or late in life. In the present study, two children of the DAISY cohort were found to express either GAA or IAA in their first sample at 9 months of age. Both of these children developed second autoantibodies (IAA or GAA) 3-6 months later, and one developed a third autoantibody (ICA512AA) at the age of 2.4 yr. In contrast, one identical twin of a patient with type I diabetes (patient 4516) developed his first autoantibody (GAA) at the age of 51 yr and his second (IAA) at the age of 60.9 yr. As the expression of multiple autoantibodies is associated with a high risk of progression to diabetes (6), long term follow-up is necessary to define diabetes risk among relatives of patients with type I diabetes.
We observed eight relatives who expressed GAA first and four who expressed IAA first among those eventually expressing more than one autoantibody. To date, no relative has first expressed ICA512AA, although we have observed individuals who expressed only ICA512AA. The pattern of appearance of detectable humoral autoimmunity to different islet-related antigens appears to be constrained, with early responses usually limited to GAD65 and insulin, followed by a later response to ICA512 / IA-2. More individuals need to be followed for longer periods to demonstrate a clear hierarchy of autoantibody appearance. In summary, we conclude that antiislet autoantibodies tend to be expressed sequentially and not simultaneously. All three autoantibodies (GAA, IAA, and ICA512AA) can develop very early in life, but GAA and IAA usually appear before ICA512AA. We speculate that these observations are most consistent with chronic progressive /3-cell destruction associated with spreading of humoral autoimmunity to multiple autoantigens with time (15,16). Such sequential appearance of autoantibodies can occur at any age, and thus, repetitive testing over time will be necessary to identify high risk individuals.
